2010 Update: Guidelines for the Management of Benign Prostatic Hyperplasia

Overview

Journal Can Urol Assoc J

Specialty Urology

Date 2010 Oct 15

PMID 20944799

Citations 45

Authors

J Curtis Nickel

Carlos E Mendez-Probst

Thomas F Whelan

Ryan F Paterson

Hassan Razvi

Affiliations

Soon will be listed here.

Citing Articles

Outcomes of Prostatic Artery Embolization for Treating Benign Prostatic Hyperplasia Symptoms: A Prospective Single-Center Study.

Delazar S, Azadnajafabad S, Firouznia K, Nowroozi M, Amini E, Fotouhi M Health Sci Rep. 2025; 8(3):e70565.

PMID: 40078904 PMC: 11896813. DOI: 10.1002/hsr2.70565.

Alpha-adrenergic antagonists and iris dynamics: Challenges and solutions in cataract surgery.

Kaushik J, Sharma R, Goyal S, Dangi M, Jha R, Singh A BMC Ophthalmol. 2024; 24(1):431.

PMID: 39363270 PMC: 11451146. DOI: 10.1186/s12886-024-03705-1.

Five-alpha reductase inhibitors and risk of prostate cancer among men with benign prostatic hyperplasia: A historical cohort study using primary care data.

Thakrar D, Douglas I, Smeeth L, Bhaskaran K Wellcome Open Res. 2024; 8:295.

PMID: 38774490 PMC: 11106599. DOI: 10.12688/wellcomeopenres.19566.1.

Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis.

Yoosuf B, Panda A, Kt M, Bharti S, Devana S, Bansal D Sci Rep. 2024; 14(1):11116.

PMID: 38750153 PMC: 11096304. DOI: 10.1038/s41598-024-61977-5.

Safety of transurethral resection of large prostate.

Al-Bakri A, Al-Jaser A, Al-Gamdi K, Al-Reshaid R, Al-Enizi A, Al-Kharji A Urol Ann. 2023; 15(2):162-165.

PMID: 37304516 PMC: 10252772. DOI: 10.4103/ua.ua_192_21.

References

Lucas M, Stephenson T, Nargund V . Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int. 2005; 95(3):354-7. DOI: 10.1111/j.1464-410X.2005.05299.x. View

Levitt J, Slawin K . Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression. Curr Urol Rep. 2008; 8(4):269-74. DOI: 10.1007/s11934-007-0072-y. View

Roehrborn C, Siami P, Barkin J, Damiao R, Major-Walker K, Morrill B . The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2007; 179(2):616-21. DOI: 10.1016/j.juro.2007.09.084. View

Bouza C, Lopez T, Magro A, Navalpotro L, Amate J . Systematic review and meta-analysis of Transurethral Needle Ablation in symptomatic Benign Prostatic Hyperplasia. BMC Urol. 2006; 6:14. PMC: 1538609. DOI: 10.1186/1471-2490-6-14. View

Karaman M, Kaya C, Ozturk M, Gurdal M, Kirecci S, Pirincci N . Comparison of transurethral vaporization using PlasmaKinetic energy and transurethral resection of prostate: 1-year follow-up. J Endourol. 2005; 19(6):734-7. DOI: 10.1089/end.2005.19.734. View

Anderson J, Roehrborn C, Schalken J, Emberton M . The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol. 2001; 39(4):390-9. DOI: 10.1159/000052475. View

Chapple C . Alpha adrenoceptor antagonists in the year 2000: is there anything new?. Curr Opin Urol. 2001; 11(1):9-16. DOI: 10.1097/00042307-200101000-00002. View

Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Montorsi F . Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010; 362(13):1192-202. DOI: 10.1056/NEJMoa0908127. View

McConnell J, Bruskewitz R, Walsh P, Andriole G, Lieber M, HOLTGREWE H . The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998; 338(9):557-63. DOI: 10.1056/NEJM199802263380901. View

10.

Hai M . Photoselective vaporization of prostate: five-year outcomes of entire clinic patient population. Urology. 2009; 73(4):807-10. DOI: 10.1016/j.urology.2008.08.502. View

11.

Madersbacher S, Lackner J, Brossner C, Rohlich M, Stancik I, Willinger M . Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23,123 cases. Eur Urol. 2005; 47(4):499-504. DOI: 10.1016/j.eururo.2004.12.010. View

12.

Bosch J, Bangma C, Groeneveld F, Bohnen A . The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. Eur Urol. 2007; 53(4):819-25. DOI: 10.1016/j.eururo.2007.08.042. View

13.

Hill B, Belville W, Bruskewitz R, Issa M, Perez-Marrero R, Roehrborn C . Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol. 2004; 171(6 Pt 1):2336-40. DOI: 10.1097/01.ju.0000127761.87421.a0. View

14.

Yang Q, Peters T, Donovan J, Wilt T, Abrams P . Transurethral incision compared with transurethral resection of the prostate for bladder outlet obstruction: a systematic review and meta-analysis of randomized controlled trials. J Urol. 2001; 165(5):1526-32. View

15.

de la Rosette J, Laguna M, Gravas S, de Wildt M . Transurethral microwave thermotherapy: the gold standard for minimally invasive therapies for patients with benign prostatic hyperplasia?. J Endourol. 2003; 17(4):245-51. DOI: 10.1089/089277903765444393. View

16.

Boyle P, Robertson C, Mazzetta C, KEECH M, Hobbs R, Fourcade R . The relationship between lower urinary tract symptoms and health status: the UREPIK study. BJU Int. 2003; 92(6):575-80. DOI: 10.1046/j.1464-410x.2003.04448.x. View

17.

Tsukamoto T, Masumori N, Rahman M, Crane M . Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally. Int J Urol. 2007; 14(4):321-4. DOI: 10.1111/j.1442-2042.2007.01596.x. View

18.

. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003; 170(2 Pt 1):530-47. DOI: 10.1097/01.ju.0000078083.38675.79. View

19.

Madersbacher S, Schatzl G, Djavan B, Stulnig T, Marberger M . Long-term outcome of transrectal high- intensity focused ultrasound therapy for benign prostatic hyperplasia. Eur Urol. 2000; 37(6):687-94. DOI: 10.1159/000020219. View

20.

Marks L, Roehrborn C, Andriole G . Prevention of benign prostatic hyperplasia disease. J Urol. 2006; 176(4 Pt 1):1299-306. DOI: 10.1016/j.juro.2006.06.022. View